Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Immutep (IMMP) will present survival data from two clinical trials of eftilagimod alfa at international oncology congresses in November and December 2026.

Rhea-AI Summary

Immutep (IMMP) will present survival data from two clinical trials of eftilagimod alfa at international oncology congresses in November and December 2026.

The EFTISARC-NEO Phase II poster on November 19 at CTOS in Seoul will cover disease-free survival in patients with operable soft tissue sarcoma receiving efti, pembrolizumab and radiotherapy before surgery. The TACTI-003 Part B poster on December 14 at ESMO Immuno-Oncology & Advanced Therapies in London will report final median overall survival results for efti plus pembrolizumab as first-line treatment for recurrent or metastatic head and neck cancer in patients with a PD-L1 combined positive score below 1.

Historical Context

1 past event · Latest: Oct 23

1 event

1. Oct 23

   Clinical trial data

   24h Move

   +0.9%

   Earlier EFTISARC-NEO report disclosed significant quality-of-life improvements and a 51.5% median tumour hyalinization result.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neoadjuvant, overall survival, pd-l1 combined positive score (cps)

3 terms

neoadjuvant medical

"in the neoadjuvant treatment of patients with resectable soft tissue sarcoma"

"Neoadjuvant" describes treatments or interventions that are given before the main or primary procedure, such as surgery or a major decision. It’s like preparing the ground before planting seeds, aiming to improve the final outcome. For investors, understanding neoadjuvant approaches can provide insight into how companies enhance results or effectiveness in their processes or products.

overall survival medical

"final median overall survival results will be presented from Part B"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

pd-l1 combined positive score (cps) medical

"a PD-L1 combined positive score (CPS) of less than 1"

A pathology score that quantifies PD-L1 protein expression by counting PD-L1–positive tumor cells plus PD-L1–positive immune cells (mainly lymphocytes and macrophages), dividing that sum by the total number of viable tumor cells, and multiplying by 100; the result is reported as an integer (commonly capped at 100). CPS is used on stained tumor tissue sections to categorize how much PD-L1 is present across both tumor and infiltrating immune cells and is distinct from Tumor Proportion Score (TPS), which counts only PD-L1–positive tumor cells. Different diagnostic assays and antibody clones can yield different CPS values, so scoring follows the specific test's protocol and pathology guidelines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SYDNEY, AUSTRALIA, Nov. 05, 2026 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that data from two clinical trials of its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), will be presented in poster presentations at two international congresses in November and December 2026.

At the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place 18–21 November 2026 in Seoul, South Korea, survival data will be presented from the investigator-initiated EFTISARC-NEO Phase II trial evaluating efti in combination with KEYTRUDA^® (pembrolizumab) and radiotherapy in the neoadjuvant treatment of patients with resectable soft tissue sarcoma.

At the ESMO Immuno-Oncology & Advanced Therapies Congress 2026, taking place 14–16 December 2026 in London, United Kingdom, final median overall survival results will be presented from Part B of the TACTI-003 Phase IIb trial evaluating efti in combination with KEYTRUDA^® in first-line recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients with a PD-L1 combined positive score (CPS) of less than 1.

CTOS 2026 Annual Meeting

Title	Disease Free Survival (DFS) in Patients with Resectable Soft Tissue Sarcoma (STS) from Eftisarc-Neo Phase II Trial of Neoadjuvant Eftilagimod Alfa (Efti), Pembrolizumab and Radiotherapy (Rth)
Trial	EFTISARC-NEO (investigator-initiated Phase II; NCT06128863)
Session category	Poster Discussion (SESSION 6)
First Author	Pawel Sobczuk, MD PhD; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Mazowieckie, Poland
Poster session	19 November 2026, 04:30 p.m. KST (19 November, 06:30 p.m. AEDT)

ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Title	Eftilagimod Alfa and Pembrolizumab in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with PD-L1 CPS <1: Final Results from the TACTI-003 Study
Trial	TACTI-003 Part B (Phase II; NCT04811027)
Session category	Poster Display session
First Author	Claus A. Kristensen, MD PhD, Copenhagen University Hospital, Copenhagen, Denmark
Poster session	14 December 2026, 17:30 GMT (15 December 2026, 4:30am AEDT)

Details of the presentations are set out below. The data will be made available on the Posters & Publications page of Immutep’s website following their presentation.

About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

This announcement was authorised for release by the CEO of Immutep Limited.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

US Investors/Media
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com